QQQ   353.15 (+1.24%)
AAPL   180.57 (+1.55%)
MSFT   325.26 (+0.58%)
META   264.58 (+0.37%)
GOOGL   122.14 (-0.29%)
AMZN   124.25 (+2.49%)
TSLA   234.86 (+4.58%)
NVDA   385.10 (+2.76%)
NIO   7.79 (+0.39%)
BABA   86.14 (+1.01%)
AMD   121.05 (+2.73%)
T   16.07 (-0.25%)
F   13.58 (-0.07%)
MU   65.32 (-2.59%)
CGC   0.69 (-4.14%)
GE   106.06 (-0.02%)
DIS   92.53 (+0.01%)
AMC   4.68 (-1.06%)
PFE   39.09 (+0.51%)
PYPL   64.24 (+0.31%)
NFLX   409.37 (+2.40%)
QQQ   353.15 (+1.24%)
AAPL   180.57 (+1.55%)
MSFT   325.26 (+0.58%)
META   264.58 (+0.37%)
GOOGL   122.14 (-0.29%)
AMZN   124.25 (+2.49%)
TSLA   234.86 (+4.58%)
NVDA   385.10 (+2.76%)
NIO   7.79 (+0.39%)
BABA   86.14 (+1.01%)
AMD   121.05 (+2.73%)
T   16.07 (-0.25%)
F   13.58 (-0.07%)
MU   65.32 (-2.59%)
CGC   0.69 (-4.14%)
GE   106.06 (-0.02%)
DIS   92.53 (+0.01%)
AMC   4.68 (-1.06%)
PFE   39.09 (+0.51%)
PYPL   64.24 (+0.31%)
NFLX   409.37 (+2.40%)
QQQ   353.15 (+1.24%)
AAPL   180.57 (+1.55%)
MSFT   325.26 (+0.58%)
META   264.58 (+0.37%)
GOOGL   122.14 (-0.29%)
AMZN   124.25 (+2.49%)
TSLA   234.86 (+4.58%)
NVDA   385.10 (+2.76%)
NIO   7.79 (+0.39%)
BABA   86.14 (+1.01%)
AMD   121.05 (+2.73%)
T   16.07 (-0.25%)
F   13.58 (-0.07%)
MU   65.32 (-2.59%)
CGC   0.69 (-4.14%)
GE   106.06 (-0.02%)
DIS   92.53 (+0.01%)
AMC   4.68 (-1.06%)
PFE   39.09 (+0.51%)
PYPL   64.24 (+0.31%)
NFLX   409.37 (+2.40%)
QQQ   353.15 (+1.24%)
AAPL   180.57 (+1.55%)
MSFT   325.26 (+0.58%)
META   264.58 (+0.37%)
GOOGL   122.14 (-0.29%)
AMZN   124.25 (+2.49%)
TSLA   234.86 (+4.58%)
NVDA   385.10 (+2.76%)
NIO   7.79 (+0.39%)
BABA   86.14 (+1.01%)
AMD   121.05 (+2.73%)
T   16.07 (-0.25%)
F   13.58 (-0.07%)
MU   65.32 (-2.59%)
CGC   0.69 (-4.14%)
GE   106.06 (-0.02%)
DIS   92.53 (+0.01%)
AMC   4.68 (-1.06%)
PFE   39.09 (+0.51%)
PYPL   64.24 (+0.31%)
NFLX   409.37 (+2.40%)
NASDAQ:KZR

Kezar Life Sciences (KZR) Stock Forecast, Price & News

$2.47
-0.44 (-15.12%)
(As of 06/8/2023 ET)
Compare
Today's Range
$2.46
$2.91
50-Day Range
$2.34
$3.16
52-Week Range
$2.25
$11.02
Volume
1.25 million shs
Average Volume
871,238 shs
Market Capitalization
$178.85 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$17.33

Kezar Life Sciences MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.67 Rating Score
Upside/​Downside
593.3% Upside
$17.33 Price Target
Short Interest
Healthy
4.06% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-0.85
Upright™ Environmental Score
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($1.31) to ($1.39) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.54 out of 5 stars

Medical Sector

151st out of 981 stocks

Pharmaceutical Preparations Industry

63rd out of 479 stocks


KZR stock logo

About Kezar Life Sciences (NASDAQ:KZR) Stock

Kezar Life Sciences, Inc., a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States. The company's lead product candidate is zetomipzomib (KZR-616), a selective immunoproteasome inhibitor that is in Phase 2b clinical trials for various indications, including lupus nephritis, dermatomyositis, and polymyositis; Phase 1b clinical trials in systemic lupus erythematosus; and completed Phase 2a clinical trials in lupus nephritis. Its preclinical products include KZR-261, a novel first-in-class protein secretion inhibitor for the treatment of tumors resistant to traditional chemotherapeutics; and KZR-TBD for the treatment of oncology and immunology. The company was incorporated in 2015 and is headquartered in South San Francisco, California.

Receive KZR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Kezar Life Sciences and its competitors with MarketBeat's FREE daily newsletter.

KZR Stock News Headlines

Kezar Life Sciences, Inc. (NASDAQ:KZR) Short Interest Update
The single greatest medical breakthrough of all time?
We are on the cusp of a medical breakthrough. And soon, this single breakthrough could lead to the cure of over 6,000 genetic diseases, including Alzheimer's, heart disease, and even cancer! This reminds me of Amgen, where early investors made as much as 46,751% when they released their revolutionary drug to the market.
Kezar Life Sciences (NASDAQ:KZR) PT Lowered to $19.00
The single greatest medical breakthrough of all time?
We are on the cusp of a medical breakthrough. And soon, this single breakthrough could lead to the cure of over 6,000 genetic diseases, including Alzheimer's, heart disease, and even cancer! This reminds me of Amgen, where early investors made as much as 46,751% when they released their revolutionary drug to the market.
8-K: Kezar Life Sciences, Inc.
Kezar Life Sciences GAAP EPS of -$0.31
KZR Kezar Life Sciences, Inc.
Wells Fargo Reaffirms Their Buy Rating on Kezar Life Sciences (KZR)
See More Headlines

KZR Price History

KZR Company Calendar

Last Earnings
3/14/2023
Today
6/08/2023
Next Earnings (Estimated)
8/10/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:KZR
Fax
N/A
Employees
84
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$17.33
High Stock Price Forecast
$20.00
Low Stock Price Forecast
$13.00
Forecasted Upside/Downside
+495.6%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.67
Research Coverage
3 Analysts

Profitability

Net Income
$-68,240,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$3.95 per share

Miscellaneous

Free Float
66,759,000
Market Cap
$210.71 million
Optionable
Not Optionable
Beta
0.16

Key Executives

  • Mr. John Franklin FowlerMr. John Franklin Fowler (Age 50)
    Co-Founder, CEO & Director
    Comp: $919.91k
  • Dr. Christopher J. Kirk Ph.D. (Age 50)
    Co-Founder & Director
    Comp: $677.41k
  • Dr. Noreen Roth Henig M.D. (Age 58)
    Chief Medical Officer
    Comp: $722.85k
  • Dr. Jack Taunton Ph.D.
    Co-Founder
  • Mr. Marc L. BelskyMr. Marc L. Belsky (Age 68)
    CFO & Sec.
  • Ms. Gitanjali Jain
    VP of Investor Relations & External Affairs
  • Mr. Mark Schiller
    Sr. VP of Legal Affairs
  • Dr. Neel K. Anand Ph.D.
    Sr. VP of Research & Drug Discovery
  • Dr. Nick Mordwinkin Ph.D. (Age 42)
    Pharm.D., Chief Bus. Officer
  • Mr. Zung To
    Sr. VP of Clinical Devel. Operations













KZR Stock - Frequently Asked Questions

Should I buy or sell Kezar Life Sciences stock right now?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Kezar Life Sciences in the last twelve months. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" KZR shares.
View KZR analyst ratings
or view top-rated stocks.

What is Kezar Life Sciences' stock price forecast for 2023?

3 analysts have issued 1-year target prices for Kezar Life Sciences' stock. Their KZR share price forecasts range from $13.00 to $20.00. On average, they predict the company's stock price to reach $17.33 in the next twelve months. This suggests a possible upside of 495.6% from the stock's current price.
View analysts price targets for KZR
or view top-rated stocks among Wall Street analysts.

How have KZR shares performed in 2023?

Kezar Life Sciences' stock was trading at $7.04 on January 1st, 2023. Since then, KZR stock has decreased by 58.7% and is now trading at $2.91.
View the best growth stocks for 2023 here
.

Are investors shorting Kezar Life Sciences?

Kezar Life Sciences saw a decrease in short interest in May. As of May 15th, there was short interest totaling 2,940,000 shares, a decrease of 14.8% from the April 30th total of 3,450,000 shares. Based on an average daily trading volume, of 1,030,000 shares, the short-interest ratio is presently 2.9 days.
View Kezar Life Sciences' Short Interest
.

When is Kezar Life Sciences' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, August 10th 2023.
View our KZR earnings forecast
.

How were Kezar Life Sciences' earnings last quarter?

Kezar Life Sciences, Inc. (NASDAQ:KZR) posted its quarterly earnings results on Tuesday, March, 14th. The company reported ($0.25) EPS for the quarter, missing analysts' consensus estimates of ($0.24) by $0.01.

What ETFs hold Kezar Life Sciences' stock?

ETFs with the largest weight of Kezar Life Sciences (NASDAQ:KZR) stock in their portfolio include Virtus LifeSci Biotech Clinical Trials ETF (BBC), ALPS Medical Breakthroughs ETF (SBIO) and SPDR S&P Biotech ETF (XBI).Direxion Daily S&P Biotech Bull 3x Shares (LABU).

What other stocks do shareholders of Kezar Life Sciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Kezar Life Sciences investors own include VBI Vaccines (VBIV), OPKO Health (OPK), Sorrento Therapeutics (SRNE), Pfizer (PFE), VYNE Therapeutics (vyne), Dynavax Technologies (DVAX), Gilead Sciences (GILD), AbbVie (ABBV), Aldeyra Therapeutics (ALDX) and Exelixis (EXEL).

When did Kezar Life Sciences IPO?

(KZR) raised $70 million in an IPO on Thursday, June 21st 2018. The company issued 4,700,000 shares at a price of $14.00-$16.00 per share. Jefferies, Cowen, Wells Fargo Securities and William Blair served as the underwriters for the IPO.

What is Kezar Life Sciences' stock symbol?

Kezar Life Sciences trades on the NASDAQ under the ticker symbol "KZR."

Who are Kezar Life Sciences' major shareholders?

Kezar Life Sciences' stock is owned by many different retail and institutional investors. Top institutional investors include Suvretta Capital Management LLC (9.52%), BlackRock Inc. (6.16%), State Street Corp (4.47%), Sphera Funds Management LTD. (2.61%), Hood River Capital Management LLC (1.98%) and Granahan Investment Management LLC (1.55%). Insiders that own company stock include Equal Talent Investments Ltd, Franklin M Berger, Michael Kauffman and Morningside Venture Investment.
View institutional ownership trends
.

How do I buy shares of Kezar Life Sciences?

Shares of KZR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Kezar Life Sciences' stock price today?

One share of KZR stock can currently be purchased for approximately $2.91.

How much money does Kezar Life Sciences make?

Kezar Life Sciences (NASDAQ:KZR) has a market capitalization of $210.71 million. The company earns $-68,240,000.00 in net income (profit) each year or ($1.06) on an earnings per share basis.

How can I contact Kezar Life Sciences?

Kezar Life Sciences' mailing address is 4000 SHORELINE COURT SUITE 300, SOUTH SAN FRANCISCO CA, 94080. The official website for the company is www.kezarlifesciences.com. The company can be reached via phone at (650) 822-5600 or via email at ceconomides@kezarbio.com.

This page (NASDAQ:KZR) was last updated on 6/8/2023 by MarketBeat.com Staff

My Account -